HRP20080099T3 - Imidazole derivatives used as tafia inhibitors - Google Patents
Imidazole derivatives used as tafia inhibitorsInfo
- Publication number
- HRP20080099T3 HRP20080099T3 HR20080099T HRP20080099T HRP20080099T3 HR P20080099 T3 HRP20080099 T3 HR P20080099T3 HR 20080099 T HR20080099 T HR 20080099T HR P20080099 T HRP20080099 T HR P20080099T HR P20080099 T3 HRP20080099 T3 HR P20080099T3
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- cycloalkyl
- formula
- unsubstituted
- compound
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- -1 aminopyridyl Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004020186A DE102004020186A1 (de) | 2004-04-22 | 2004-04-22 | Heterocyclylessigsäuren als Inhibitoren von TAFla |
| PCT/EP2005/003630 WO2005105781A1 (de) | 2004-04-22 | 2005-04-07 | Imidazol-derivate als tafia-inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080099T3 true HRP20080099T3 (en) | 2008-03-31 |
Family
ID=34964308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080099T HRP20080099T3 (en) | 2004-04-22 | 2008-03-06 | Imidazole derivatives used as tafia inhibitors |
Country Status (35)
| Country | Link |
|---|---|
| EP (2) | EP1864979B1 (zh) |
| JP (1) | JP4939401B2 (zh) |
| KR (1) | KR101162047B1 (zh) |
| CN (1) | CN100572376C (zh) |
| AR (1) | AR053302A1 (zh) |
| AT (2) | ATE523505T1 (zh) |
| AU (1) | AU2005238144B2 (zh) |
| BR (1) | BRPI0510159A (zh) |
| CA (1) | CA2563401C (zh) |
| CR (1) | CR8650A (zh) |
| CY (1) | CY1108087T1 (zh) |
| DE (2) | DE102004020186A1 (zh) |
| DK (1) | DK1740569T3 (zh) |
| EC (1) | ECSP066941A (zh) |
| ES (1) | ES2299026T3 (zh) |
| HK (1) | HK1101823A1 (zh) |
| HR (1) | HRP20080099T3 (zh) |
| IL (1) | IL178672A (zh) |
| MA (1) | MA28543B1 (zh) |
| MY (1) | MY140903A (zh) |
| NI (1) | NI200600217A (zh) |
| NO (1) | NO20065320L (zh) |
| NZ (1) | NZ550757A (zh) |
| PE (1) | PE20060172A1 (zh) |
| PL (1) | PL1740569T3 (zh) |
| PT (1) | PT1740569E (zh) |
| RS (1) | RS50553B (zh) |
| RU (1) | RU2375356C2 (zh) |
| SI (1) | SI1740569T1 (zh) |
| TN (1) | TNSN06341A1 (zh) |
| TW (1) | TWI359016B (zh) |
| UA (1) | UA87306C2 (zh) |
| UY (1) | UY28868A1 (zh) |
| WO (1) | WO2005105781A1 (zh) |
| ZA (1) | ZA200607668B (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101553219B (zh) * | 2006-12-06 | 2013-04-24 | 塞诺菲-安万特股份有限公司 | 作为TAFIa抑制剂的脲和磺酰胺衍生物 |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| US8470863B2 (en) * | 2007-02-13 | 2013-06-25 | Merck Sharp & Dohme, Corp. | Derivatives and analogs of chroman as functionally selective ALPHA2C adrenoreceptor agonists |
| BRPI0814294A2 (pt) | 2007-07-19 | 2015-02-03 | Metabolex Inc | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. |
| EP2262783A2 (en) * | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
| NZ589671A (en) | 2008-06-06 | 2012-03-30 | Sanofi Aventis | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia |
| WO2010050525A1 (ja) | 2008-10-29 | 2010-05-06 | 大正製薬株式会社 | ＴＡＦＩａ阻害活性を有する化合物 |
| SG176558A1 (en) * | 2009-05-15 | 2012-01-30 | Sanofi Sa | Process for the preparation of a compound useful as an inhibitor of tafia |
| FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2011041154A1 (en) | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| KR20130006620A (ko) | 2010-03-18 | 2013-01-17 | 다이이찌 산쿄 가부시키가이샤 | 시클로프로판카르복실산 유도체 |
| JP5807006B2 (ja) | 2010-03-18 | 2015-11-10 | 第一三共株式会社 | シクロアルキル基で置換されたイミダゾール誘導体 |
| MX2013004193A (es) * | 2010-11-11 | 2013-06-05 | Sanofi Sa | Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico. |
| EP2782575B1 (en) | 2011-11-25 | 2016-04-20 | Sanofi | Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
| US9156815B2 (en) | 2011-11-25 | 2015-10-13 | Sanofi | Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate |
| US9102657B2 (en) * | 2011-11-25 | 2015-08-11 | Sanofi | Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid |
| EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
| US9834527B2 (en) * | 2013-06-10 | 2017-12-05 | Sanofi | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
| CN108883094A (zh) | 2016-03-29 | 2018-11-23 | 第三共株式会社 | 炎症性肠病治疗剂 |
| KR20190035752A (ko) | 2016-08-03 | 2019-04-03 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | 염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| WO2003061653A1 (en) | 2002-01-22 | 2003-07-31 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
-
2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/de not_active Withdrawn
-
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/es not_active Application Discontinuation
- 2005-04-07 DK DK05731221T patent/DK1740569T3/da active
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/de active Active
- 2005-04-07 ES ES05731221T patent/ES2299026T3/es active Active
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/pt not_active Application Discontinuation
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/de active Application Filing
- 2005-04-07 SI SI200530185T patent/SI1740569T1/sl unknown
- 2005-04-07 AT AT07017340T patent/ATE523505T1/de active
- 2005-04-07 PL PL05731221T patent/PL1740569T3/pl unknown
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-07 EP EP07017340A patent/EP1864979B1/de active Active
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 AT AT05731221T patent/ATE386737T1/de active
- 2005-04-07 PT PT05731221T patent/PT1740569E/pt unknown
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/ko not_active IP Right Cessation
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/sr unknown
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/ru not_active IP Right Cessation
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/zh not_active Expired - Fee Related
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/ja not_active Expired - Fee Related
- 2005-04-07 EP EP05731221A patent/EP1740569B1/de active Active
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 AR ARP050101556A patent/AR053302A1/es not_active Application Discontinuation
- 2005-04-20 TW TW094112493A patent/TWI359016B/zh not_active IP Right Cessation
- 2005-04-22 UY UY28868A patent/UY28868A1/es unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/ru unknown
-
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/es unknown
- 2006-09-22 CR CR8650A patent/CR8650A/es unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/fr unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/es unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/no not_active Application Discontinuation
-
2007
- 2007-09-03 HK HK07109537.4A patent/HK1101823A1/xx not_active IP Right Cessation
-
2008
- 2008-03-06 HR HR20080099T patent/HRP20080099T3/xx unknown
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080099T3 (en) | Imidazole derivatives used as tafia inhibitors | |
| RS53080B (en) | AMINOPHOSPHORIC ACID ETHAR DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS THE ACTIVE INGREDIENT | |
| MY138941A (en) | Aryl-pyridine derivatives | |
| DE602006021539D1 (en) | Morpholine als 5ht2c-agonisten | |
| TW200745032A (en) | Novel heterobicyclic derivatives | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| MX2010007977A (es) | Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica. | |
| MX2009002229A (es) | Benzotriazoles como moduladores de cinasas. | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| JP2010535870A5 (zh) | ||
| CO6241102A2 (es) | Formulaciones que contienen triazinonas y hierro | |
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| MD20110063A2 (en) | Herbicidal compositions containing benzoylpyrazole compounds | |
| EA200970161A1 (ru) | Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt | |
| MX2009004910A (es) | Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. | |
| UA96947C2 (ru) | Производные циннамоил-пиперазина и их применение как антагонистов par-1 | |
| RS54618B1 (en) | NEW S-NITROZOGLUTATION REDUCTASE INHIBITORS | |
| UA94606C2 (ru) | Производные тиоксантина, композиция, которая их содержит, и их применение в терапии | |
| UA86836C2 (ru) | Производные изоксазолина, способ их получения (варианты), гербицидная композиция и способ угнетения роста сорняков | |
| MX2009010218A (es) | Derivados de aza-piridopirimidinona. | |
| EP1921077A4 (en) | AGENT FOR THE TREATMENT AND / OR PREVENTION OF SLEEP DISORDERS | |
| UA90742C2 (en) | Pyrazolone derivatives | |
| TW200504085A (en) | Derivatives of [2-(8,9-dioxo-2, 6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof | |
| TW200745063A (en) | Triazolone derivatives | |
| PL1685142T3 (pl) | Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera |